Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Note to drug sponsors: all EU trial results to be posted from July

This article was originally published in SRA

Executive Summary

Amid the furore over the European Medicines Agency's policy on proactive publication of clinical trial data, which is expected to come into effect in October, it's easy to forget that an earlier deadline is in the offing.

You may also be interested in...



Roche Fined For Anticompetitive Behavior In Romania

Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products. 

EU Parallel Trade: The ‘Most Effective Savings Tool Available’

The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.

EMA Suspends Leo’s Actinic Keratosis Drug Picato

The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.

UsernamePublicRestriction

Register

PS117846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel